昭衍新药获董监高累计减持约42.24万股股份

Core Viewpoint - The company, Zhaoyan New Drug (603127), announced a share reduction plan by its executives, which will take place from September 30, 2025, to November 28, 2025, involving a total reduction of up to 848,300 shares, representing 0.1132% of the company's total share capital [1] Summary by Sections Share Reduction Plan - The executives involved in the share reduction include Vice General Manager Sun Yunxia, General Manager and Board Secretary Gao Dapeng, Vice General Manager Gu Jingliang, Supervisor Li Ye, and Chief Financial Officer Yu Aishui [1] - The planned reduction will occur through block trading or centralized bidding on the Shanghai Stock Exchange [1] - The total shares to be reduced are broken down as follows: up to 674,700 shares by Sun Yunxia, 72,100 shares by Gao Dapeng, 67,400 shares by Gu Jingliang, 25,600 shares by Li Ye, and 8,500 shares by Yu Aishui [1] Execution of the Plan - As of November 28, 2025, the actual shares reduced were: 319,940 shares by Sun Yunxia, 25,500 shares by Gao Dapeng, 66,500 shares by Gu Jingliang, 2,000 shares by Li Ye, and 8,500 shares by Yu Aishui [1] - The reduction plan was completed within the specified timeframe [1]